Pfizer announced Monday that they have launched mid-to-late-stage trials on their newly developed oral antiviral drug that could prevent COVID-19.
The trials will test some 2,660 adults who are living with a symptomatic coronavirus patient.
These adults will also get a small dose of Ritonavir, an antiviral drug designed to tackle HIV, along with a dose of the COVID-19 candidate drug.
One third of the group will be given placebos.
Pfizer is also working on an oral treatment pill for COVID-19 and the results of that study are expected later this year.